Dublin, March 27, 2025 (GLOBE NEWSWIRE) -- The "Paclitaxel Injection Market Report 2025"has been added to ResearchAndMarkets.com's offering. This report covers market characteristics, size and ...

ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer. We enrolled 4950 women with axillary ...

LONDON, England—While it’s not clear sirolimus-based devices will ever overtake the old workhorse paclitaxel, data from several studies presented here at the 2025 Charing Cross International Symposium ...

Details concerning the Paclitaxel combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments ...

Results showed the ORR was 17.1% in the tovecimig plus paclitaxel arm compared with 5.3% in the paclitaxel alone arm. Topline data were announced from a phase 2/3 trial evaluating tovecimig in ...

The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel plus cisplatin with intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel ...

WASHINGTON, DC—A sirolimus drug-coated balloon (DCB) is noninferior to paclitaxel-coated DCBs for the treatment of femoropopliteal artery disease, according to data from the SIRONA trial, the first ...

Dublin, March 27, 2025 (GLOBE NEWSWIRE) -- The "Paclitaxel Injection Market Report 2025"has been added to ResearchAndMarkets.com's offering. This report covers market characteristics, size and growth, ...